Int. J. Mol. Sci. 2013, 14(1), 30-45; doi:10.3390/ijms14010030
Review

Novel Molecular Targets for the Treatment of Gastroenteropancreatic Endocrine Tumors: Answers and Unsolved Problems

1
, 2
, 1
, 1
, 2
 and 1,*
Received: 11 October 2012; in revised form: 1 December 2012 / Accepted: 3 December 2012 / Published: 20 December 2012
(This article belongs to the Special Issue Advances in Molecular Oncology)
View Full-Text   |   Download PDF [257 KB, uploaded 19 June 2014]
Abstract: As more knowledge on molecular alterations favoring carcinogenesis and spreading of gastroenteropancreatic endocrine tumors has become available, a number of targeted agents interfering with key growth and angiogenic pathways have been explored in preclinical and clinical studies. The mTOR inhibitor Everolimus, and the multi-target antiangiogenetic agent Sunitinib, have been shown to be effective and thus have been approved by the FDA for treatment of pancreatic endocrine tumors. However, there is little data on the primary resistance to targeted agents on these tumors. The goals of the present review are to elucidate the possible advantage of combined treatments in overcoming induced resistances, and to identify biomarkers able to predict clinical efficacy. Moreover, the role of interesting targets for which a strong biological rationale exists, and specific inhibitors are available, such as the Src Family Kinases and the Hedgehog Pathway, are discussed. There is now need for more preclinical studies on cell lines and animal models to provide a stronger preclinical background in this field, as well as clinical trials specifically comparing one targeted therapy with another or combining different targeted agents.
Keywords: gastroenteropancreatic endocrine tumors; target therapy; mTOR; angiogenesis; Src; hedgehog; combined treatment; resistance
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Capurso, G.; Fendrich, V.; Rinzivillo, M.; Panzuto, F.; Bartsch, D.K.; Fave, G.D. Novel Molecular Targets for the Treatment of Gastroenteropancreatic Endocrine Tumors: Answers and Unsolved Problems. Int. J. Mol. Sci. 2013, 14, 30-45.

AMA Style

Capurso G, Fendrich V, Rinzivillo M, Panzuto F, Bartsch DK, Fave GD. Novel Molecular Targets for the Treatment of Gastroenteropancreatic Endocrine Tumors: Answers and Unsolved Problems. International Journal of Molecular Sciences. 2013; 14(1):30-45.

Chicago/Turabian Style

Capurso, Gabriele; Fendrich, Volker; Rinzivillo, Maria; Panzuto, Francesco; Bartsch, Detlef K.; Fave, Gianfranco D. 2013. "Novel Molecular Targets for the Treatment of Gastroenteropancreatic Endocrine Tumors: Answers and Unsolved Problems." Int. J. Mol. Sci. 14, no. 1: 30-45.


Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert